期刊文献+

288例手术切除的IIIA-N2非小细胞肺癌患者的生存分析 被引量:4

Survival and Progostic Factors in Resected IIIA-N2 Non-small Cell Lung Cancer:A Study of 288 Cases
下载PDF
导出
摘要 背景与目的探讨完整切除术后IIIA期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的床预后因素。方法对1999年1月至2004年12月中山大学肿瘤防治中心收治288例手术切除的IIIA期非小细胞肺癌患者进行生存分析,生存率的计算及单因素生存分析用Kaplan-Meier法,Log-rank法检验;Cox比例风险模型进行多因素分析。结果288例手术切除的IIIA期非小细胞肺癌患者的中位生存期为770天,1年、2年、3年、4年和5年的累计生存率分别为77.1%、52.4%、34.9%、28.1%和20.2%。单因素生存分析发现年龄(<60岁vs≥60岁)、是否吸烟、手术方式、T分期、术后化疗、术后化疗疗程数、术后放疗7个临床因素与IIIA期NSCLC患者术后的预后有统计学意义,进一步利用Cox比例风险模型进行多因素分析发现术后化疗、术后放疗、T分期是影响预后的独立因素。结论术后化疗、术后放疗、T分期是影响IIIA期非小细胞肺癌预后的重要因素。 Background and objective To investigate potential clinical prognostic factors in completely resected stage Ilia non-small cell lung cancer (NSCLC). Methods Proceeding survival analysis of 288 pathological Stage Ilia NSCLC patients with completely resection which in Cancer center of Sun Yat-sen University from Jan 1999 to Dec 2004.Prognostic factors were estimated using the Kaplan-Meier ang log-rank analysis. The Cox regression model evaluated the influence of factors on the survival. Results Univariate analysis identified 7 significant prognostic clinical factors including age, smoking, T stage, operative approach, postoperative chemotherapy, numbers of postoperative chemotherapy cycles, postoperative radiotherapy. In multivariate analysis, 3 independent prognostic factors entered the model: T stage, postoperative chemotherapy and postoperative radiotherapy. Conclusion T stage, postoperative chemotherapy, postoperative radiotherapy have the prognostic significance in postoperative stage IliA NSCLC.
出处 《中国肺癌杂志》 CAS 2009年第6期587-591,共5页 Chinese Journal of Lung Cancer
  • 相关文献

参考文献12

  • 1Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest, 1997, 111(6):1710-7.
  • 2吴一龙,黄植蕃,戎铁华,杨名添.基于97分期的非小细胞肺癌术后分期和生存研究[J].中华肿瘤杂志,1999,21(5):363-365. 被引量:75
  • 3Sekine I, Nishiwaki Y, Yokose T, et al. Young lung cancer patients in Japan: difereut characteristics between the sexes[J]. Ann ThoFac Surg, 1999, 67: 1451-1455.
  • 4Izbicki JR, Passlick B, Karg O, et al. Impact of radical systemic mediastinal lymphadenectomy on tumor staging in lung cancer[J]. Ann Thorac Surg,1995, 59(1): 209-214.
  • 5Izbicki JR, Passlick B, Karg O, et al. Efectiveness of radical systemic mediastinal lymphadenectomy in patients with respectable non-small cell lung cancer[J].Ann Surg, 1998, 227(1): 138-144.
  • 6Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases[J]. Ann Thorac Surg, 1997, 63(5): 1441-1450.
  • 7Andre F, Grunenwald D, Pignon J-P, et al. Survival of patients with resected N2 non-small-cen lung cancer : evidence for a sub classification and implications[J].J Clin Oncol, 2000,18( 16): 2981-2989.
  • 8王思愚,吴一龙,戎铁华,黄植藩,区伟.Ⅲ期N2非小细胞肺癌的外科治疗[J].中华肿瘤杂志,2002,24(6):605-607. 被引量:24
  • 9Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N EnglJ Med. 2004Jan 22;350(4): 351-60.
  • 10Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27.

二级参考文献15

共引文献118

同被引文献48

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部